Nasopharyngeal cancer – Trials in Disease – Overview of Information and Clinical Research

Rákkutatás · Nasopharyngeal carcinoma

This page lists four ongoing trials in Europe for nasopharyngeal cancer with different approaches including immunotherapy with nivolumab or pembrolizumab, a combination of nivolumab, cisplatin and 5‑fluorouracil for pediatric and adult patients, and a PET/CT imaging study of somatostatin receptor‑2 expression in EBV‑positive disease.

The page lists four ongoing clinical trials in Europe for nasopharyngeal cancer. Three trials evaluate immunotherapy agents (nivolumab in Poland and Germany, pembrolizumab in Italy) and one trial focuses on advanced imaging. The trials target patients with platinum‑resistant disease, EBV‑positive disease and/or recurrent or metastatic disease, and include pediatric participants in the German study. Trial designs involve induction chemotherapy with immunotherapy, combination immunotherapy‑PARP inhibition, or PET/CT imaging of somatostatin receptor‑2 expression. FDA‑approved PD‑1 inhibitors (nivolumab, pembrolizumab) are administered intravenously; olaparib is taken orally. Nivolumab dosage is 10 mg/mL IV. The trials use RECIST 1.1 criteria to measure objective response, progression‑free survival and overall survival, and record quality‑of‑life and safety outcomes.

The trials provide new treatment options for a disease that is often refractory to standard platinum‑based chemotherapy, especially in the EBV‑associated, metastatic and pediatric sub‑groups. Potential improvements in response rate, progression‑free survival and overall survival could significantly change clinical practice.

Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Eredeti forrás

Kapcsolódó jelek